BDBM528084 N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US11180484, Example 6

SMILES COc1ccnc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C(F)(F)F)c1F

InChI Key InChIKey=NKTBXDIJVDKJRR-UHFFFAOYSA-N

Data  23 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 23 hits for monomerid = 528084   

TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50:  3.20nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))TBA
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human thrombinMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+3nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma serine protease inhibitor(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))TBA
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine protease 1(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of hERG expressed in CHO cells by whole cell patch clamp assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 1A2(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP1A2 in human liver microsomes assessed as reduction in acetaminophen metabolite formation incubated for 30 mins in presence of NADPH...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4 hydroxy-diclofenac metabolite formation incubated for 30 mins in presence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP2C19 in human liver microsomes assessed as reduction in 4-hydroxymephenytoin metabolite formation incubated for 30 mins in presence ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP2D6 in human liver microsomes assessed as reduction in dextrorphan metabolite formation incubated for 30 mins in presence of NADPH b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6beta-hydroxymidazolam metabolite formation using midazolam as substrate incu...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >2.50E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6beta-hydroxytestosterone metabolite formation using testosterone as substrat...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50:  76nMAssay Description:Inhibition of DXS induced human whole plasma kallikrein using H-D-Pro-Phe-Arg-AFC as substrate preincubated for 5 mins followed by DXS stimulation by...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50:  3.20nMAssay Description:Inhibition of plasma kallikrein (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetKallikrein-1(Homo sapiens (Human))TBA
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+3nMAssay Description:Inhibition of KLK1 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCoagulation factor XI(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human fXIa using Z-Gly-Pro-Arg-AFC as substrateMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetCoagulation factor XII(Homo sapiens (Human))
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+3nMAssay Description:Inhibition of human fXIIa using H-DPro-Phe-Arg-AFC as substrateMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human trypsinMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasminogen(Homo sapiens (Human))TBA
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human plasminMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetKallikrein-1(Homo sapiens (Human))TBA
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: >4.00E+3nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent